Patents by Inventor Matthew Paul Bourbeau

Matthew Paul Bourbeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS
    Publication number: 20240124442
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 3, 2022
    Publication date: April 18, 2024
    Applicant: AMGEN INC.
    Inventors: Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Kevin Lloyd GREENMAN, Todd J. KOHN, Kexue LI, Qingyian LIU, Ana Elena MINATTI, Primali Vasundera NAVARATNE, Liping H. PETTUS, Rene RAHIMOFF, Hui-Ling WANG, Nicholas Anthony WEIRES
  • TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS
    Publication number: 20240101570
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).
    Type: Application
    Filed: November 22, 2021
    Publication date: March 28, 2024
    Inventors: Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Francesco MANONI, Primali Vasundera NAVARATNE, Liping H. PETTUS, Rene RAHIMOFF, Nuria A. TAMAYO, Mikkel VESTERGAARD, Hui-Ling WANG, Nicholas Anthony WEIRES
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20240092794
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 21, 2024
    Applicant: AMGEN INC.
    Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
  • PRMT5 inhibitors
    Patent number: 11845760
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: December 19, 2023
    Assignee: AMGEN INC.
    Inventors: Shon Booker, Matthew Paul Bourbeau, John R. Butler, Sanne Ormholt Schroder Glad, Brian Alan Lanman, Patricia Lopez, Francesco Manoni, Liping H. Pettus, Ian Sarvary, Nuria A. Tamayo, Mikkel Vestergaard, Nicholas Anthony Weires
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20230159510
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 11, 2021
    Publication date: May 25, 2023
    Applicant: AMGEN INC.
    Inventors: Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
  • KIF18A INHIBITORS
    Publication number: 20220289724
    Abstract: Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, such as cancer, psoriasis, atopic dermatitis, an autoimmune disorder, or inflammatory bowel disease, and the like.
    Type: Application
    Filed: August 3, 2020
    Publication date: September 15, 2022
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Jian Jeffrey CHEN, Matthew Paul BOURBEAU, Matthew Richard KALLER, Jonathan Dante LOW, Ana Elena MINATTI, Thomas T. NGUYEN, Nobuko NISHIMURA, Liping H. PETTUS, Mary Catherine WALTON, Qiufen May XUE, John Gordon ALLEN
  • KIF18A INHIBITORS
    Publication number: 20220281843
    Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: August 3, 2020
    Publication date: September 8, 2022
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Matthew Paul BOURBEAU
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20220194955
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 23, 2022
    Applicant: AMGEN INC.
    Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
  • KIF18A INHIBITORS
    Publication number: 20220106293
    Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 14, 2021
    Publication date: April 7, 2022
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA
  • KIF18A INHIBITORS
    Publication number: 20220073504
    Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Applicant: AMGEN INC.
    Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, JAMES ALEXANDER BROWN, MICHAEL J FROHN, JIAN JEFFREY CHEN, KEXUE LI, QINGYIAN LIU, JONATHAN DANTE LOW, VU MA, LIPING H PETTUS, MARY CATHERINE WALTON, ANA ELENA MINATTI, MATTHEW PAUL BOURBEAU, LEI JIA, THOMAS T NGUYEN, NOBUKO NISHIMURA, QIUFEN MAY XUE, JOHN GORDON ALLEN
  • KIF18A INHIBITORS
    Publication number: 20220056015
    Abstract: The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 24, 2022
    Applicant: AMGEN INC.
    Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, JIAN JEFFREY CHEN, KEXUE LI, LIPING H. PETTUS, MATTHEW PAUL BOURBEAU, LEI JIA
  • KIF18A inhibitors
    Patent number: 11236069
    Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: February 1, 2022
    Assignee: AMGEN INC.
    Inventors: Nuria A. Tamayo, Abhisek Banerjee, Jian Jeffrey Chen, Jonathan Dante Low, Ana Elena Minatti, Matthew Paul Bourbeau
  • KIF18A INHIBITORS
    Publication number: 20220002311
    Abstract: The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: January 6, 2022
    Applicant: AMGEN INC.
    Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, MICHAEL J FROHN, JIAN JEFFREY CHEN, KEXUE LI, MATTHEW PAUL BOURBEAU, LEI JIA, MATTHEW RICHARD KALLER, THOMAS T NGUYEN, NOBUKO NISHIMURA, QIUFEN MAY XUE, JOHN GORDON ALLEN
  • KIF18A INHIBITORS
    Publication number: 20200239441
    Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 30, 2020
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J. FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA
  • Pyrazine compounds as phosphodiesterase 10 inhibitors
    Patent number: 8329700
    Abstract: Pyrazine compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein m, n, p, R1, R2, R3, R4, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, Y and Z are defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: December 11, 2012
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Matthew Paul Bourbeau, Ning Chen, Essa Hu, Roxanne Kunz, Shannon Rumfelt
  • Thiadiazole compounds and methods of use
    Patent number: 7354944
    Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: April 8, 2008
    Assignee: Amgen Inc.
    Inventors: Qingping Zeng, Guomin Yao, George Erich Wohlhieter, Vellarkad N. Viswanadhan, Andrew Tasker, James Thomas Rider, Holger Monenschein, Celia Dominguez, Matthew Paul Bourbeau